First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- 18 May 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 21 (6), 821-831
- https://doi.org/10.1016/s1470-2045(20)30169-8
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- MSIsensor: microsatellite instability detection using paired tumor-normal sequence dataBioinformatics, 2013
- Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With TrastuzumabJournal of Clinical Oncology, 2013
- Effective Anti-Neu–Initiated Antitumor Responses Require the Complex Role of CD4+ T CellsClinical Cancer Research, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Human Epidermal Growth Factor Receptor 2 Testing in Gastroesophageal Cancer: Correlation Between Immunohistochemistry and Fluorescence In Situ HybridizationArchives of Pathology & Laboratory Medicine, 2011
- T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survivalBritish Journal of Cancer, 2011
- Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapyProceedings of the National Academy of Sciences of the United States of America, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive ImmunityCancer Cell, 2010
- Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and ChemotherapyClinical Cancer Research, 2007